Doliver Capital Advisors LP lifted its stake in Merck & Co., Inc. (NYSE:MRK) by 19.2% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 6,699 shares of the company’s stock after purchasing an additional 1,077 shares during the quarter. Doliver Capital Advisors LP’s holdings in Merck & Co., Inc. were worth $365,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in MRK. Blackhill Capital Inc. lifted its stake in shares of Merck & Co., Inc. by 14.9% during the 1st quarter. Blackhill Capital Inc. now owns 227,750 shares of the company’s stock worth $12,406,000 after acquiring an additional 29,550 shares during the last quarter. State of New Jersey Common Pension Fund D lifted its stake in shares of Merck & Co., Inc. by 5.2% during the 1st quarter. State of New Jersey Common Pension Fund D now owns 4,020,000 shares of the company’s stock worth $218,969,000 after acquiring an additional 200,000 shares during the last quarter. Breiter Capital Management Inc. lifted its stake in shares of Merck & Co., Inc. by 110.3% during the 1st quarter. Breiter Capital Management Inc. now owns 9,292 shares of the company’s stock worth $506,000 after acquiring an additional 4,874 shares during the last quarter. Aperio Group LLC lifted its stake in shares of Merck & Co., Inc. by 2.9% during the 1st quarter. Aperio Group LLC now owns 1,430,443 shares of the company’s stock worth $77,916,000 after acquiring an additional 40,679 shares during the last quarter. Finally, Sawtooth Solutions LLC lifted its stake in shares of Merck & Co., Inc. by 9.2% during the 1st quarter. Sawtooth Solutions LLC now owns 44,627 shares of the company’s stock worth $2,431,000 after acquiring an additional 3,747 shares during the last quarter. Hedge funds and other institutional investors own 73.05% of the company’s stock.

A number of brokerages recently issued reports on MRK. TheStreet raised Merck & Co., Inc. from a “c+” rating to a “b-” rating in a research note on Friday, June 8th. Zacks Investment Research raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $69.00 target price for the company in a research report on Thursday, June 7th. BMO Capital Markets lifted their target price on Merck & Co., Inc. from $65.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday, April 26th. Deutsche Bank reaffirmed a “hold” rating on shares of Merck & Co., Inc. in a research report on Wednesday, April 25th. Finally, Goldman Sachs Group raised Merck & Co., Inc. from a “neutral” rating to a “buy” rating and decreased their target price for the company from $60.15 to $58.83 in a research report on Monday, April 23rd. One investment analyst has rated the stock with a sell rating, six have given a hold rating and fifteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $66.05.

Merck & Co., Inc. opened at $62.44 on Wednesday, according to MarketBeat Ratings. The firm has a market capitalization of $168.05 billion, a PE ratio of 15.02, a P/E/G ratio of 2.24 and a beta of 0.76. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.42 and a quick ratio of 1.10. Merck & Co., Inc. has a 12 month low of $52.83 and a 12 month high of $66.41.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, May 1st. The company reported $1.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.00 by $0.05. The firm had revenue of $10.04 billion during the quarter, compared to analyst estimates of $10.09 billion. Merck & Co., Inc. had a return on equity of 30.93% and a net margin of 4.31%. The business’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.88 EPS. research analysts expect that Merck & Co., Inc. will post 4.23 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, July 9th. Stockholders of record on Friday, June 15th will be given a $0.48 dividend. This represents a $1.92 annualized dividend and a dividend yield of 3.07%. The ex-dividend date is Thursday, June 14th. Merck & Co., Inc.’s payout ratio is 48.24%.

In other news, EVP Julie L. Gerberding sold 9,972 shares of the business’s stock in a transaction on Tuesday, May 15th. The stock was sold at an average price of $59.66, for a total value of $594,929.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Weir Mirian M. Graddick sold 24,000 shares of the business’s stock in a transaction on Monday, April 16th. The stock was sold at an average price of $58.00, for a total value of $1,392,000.00. The disclosure for this sale can be found here. Insiders own 0.32% of the company’s stock.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.